医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

SanBio Announces Pricing of Initial Public Offering on Tokyo Stock Exchange

2015年04月08日 PM09:30
このエントリーをはてなブックマークに追加


 

TOKYO & MOUNTAIN VIEW, Calif.

SanBio, Co. Ltd. announced today the pricing of an initial public offering of 4,000,000 shares, or 8.6 percent of its common stock, at an offer price of 2,000 Japanese Yen per share. The shares have been offered by SanBio, Co. Ltd.

SanBio’s common stock is expected to begin trading on the Tokyo Stock Exchange today, April 8, 2015, on Mothers (market of the high-growth and emerging stocks). The ticker symbol is “4592.” Nomura Securities is acting as a lead underwriter.

SanBio is a regenerative medicine company with stem cell therapies in various stages of development and clinical trial testing. Its proprietary stem cell therapy, SB623, is expected to begin Phase-2b clinical trials for treatment of chronic stroke and Phase 2 clinical trials for treatment of traumatic brain injury later in 2015.

Based in Tokyo, the company also has a United States headquarters in Mountain View, CA and is led by Co-CEOs Keita Mori and Toru Kawanishi.

Said Mori, “This is a pivotal time for the field of regenerative medicine, and we are proud to be developing therapies for some of the most debilitating neurological disorders. We look forward to having our stock trade on the Tokyo Stock Exchange.”

CONTACT

SanBio
Wei Ling Kwok, 650-625-8965 x 10
weiling.kwok@san-bio.com
or
PadillaCRT
Kris
Patrow, 612-455-1748
kris.patrow@padillacrt.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Orthocell Granted European Tendon Regeneration Patent
  • Clover Biopharmaceuticals Completes RMB 62.8 Million Series A Financing
  • 三叶草生物制药完成6,280万元人民币A轮融资
  • Corindus Announces First Commercial Installation of CorPath® GRX System Outside of U.S.
  • Walmart, JD.com, IBM and Tsinghua University Launch a Blockchain Food Safety Alliance in China